论文部分内容阅读
本文收集复治肺结核病例104例,对免疫增强剂(斯奇康)免疫治疗效果进行回顾性分析。 资料与方法:复治肺结核104例。分为治疗组53例,男31例,女22例,平均42.3岁。对照组51例,男28例,女23例,平均39.6岁。抗结核治疗方案采用WHO推荐的复治治疗方案(2SHRZE/1HRZE/5HRE),治疗组辅助加用斯奇康注射液,对照组仅给予抗结核治疗。疗效判定以痰菌变化、影像变化、空洞变化为指标。
In this paper, 104 cases of re-treatment of pulmonary tuberculosis cases were collected, and the immunotherapy of immunostimulants (schiskan) was retrospectively analyzed. Materials and Methods: 104 cases of pulmonary tuberculosis. 53 cases were divided into treatment group, 31 males and 22 females, average 42.3 years old. The control group of 51 patients, 28 males and 23 females, with an average of 39.6 years old. Antituberculosis treatment regimen recommended by the WHO retreatment program (2SHRZE / 1HRZE / 5HRE), the treatment group assisted with Stichikkol injection, the control group was given only anti-TB treatment. Curative determination of sputum bacteria change, image changes, empty change as an indicator.